At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
autologous muscle cell injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Muscle Cell Mediated Therapy for Stress Urinary Incontinence: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells.
In Brief
A Phase 2 clinical trial evaluating autologous muscle cell injection for Stress Urinary Incontinence and Cell Therapy. Completed, enrolled 66 participants across 3 sites in 2 countries.
Detailed Summary
This is a clinical investigation approved by US FDA and Canadian Health Authority to study the safety and potential effectiveness of the autologous muscle cells for the treatment of stress urinary incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Urinary Incontinence, Cell Therapy
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedFeb 2009
Primary CompletionNov 2011
TodayJul 2026
First PostedFeb 19, 2009
Enrollment StartOct 9, 2008
Primary CompletionNov 2, 2011
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.4 years ago
Interventions
autologous muscle cell injectionbiological
Injection of autologous muscle cells